Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $62 from $65 and keeps an ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high ...

Ionis Pharmaceuticals Inc. ( (IONS) ) has released its Q3 earnings. Here is a breakdown of the information Ionis Pharmaceuticals Inc. presented ...

Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 22.8% in the 3rd quarter, according to its most recent 13F filing ...